

Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FormÂ 6-KÂ REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE13a-16 OR 15d-16 UNDERTHE SECURITIES EXCHANGE ACT OF 1934Â Forthe month of January, 2025Â CommissionFile NumberÂ 001-41666Â CASI PHARMACEUTICALS,Â INC. (Translation of registrantâ€™s name into English)Â 1701-1702, China Central Office Tower 1No.Â 81 Jianguo Road, Chaoyang DistrictBeijing, 100025Peopleâ€™s Republic of China(Address of principal executive office)Â Indicateby check mark whether the registrant files or will file annual reports under cover FormÂ 20-F or FormÂ 40-F.Â FormÂ 20-FÂ xÂ Â FormÂ 40-FÂ Â Â Â Â Â CASIPharmaceuticals Receives Asset Freezing Order from Court of P.R. ChinaÂ OnJanuaryÂ 21, 2025, CASI Pharmaceuticals,Â Inc., a Cayman Islands incorporated company (â€œCASIâ€ or the â€œCompanyâ€)announced that the Company received on JanuaryÂ 17, 2025 an asset freezing order (the â€œAsset Freezing Orderâ€) from a court of P.R.C. with respect to the Companyâ€™s previously announced dispute with Juventas Cell Therapy Ltd. (â€œJuventasâ€) andthe related arbitration proceedings initiated at the Hong Kong International Arbitration Centre in connection to Juventasâ€™s purportedtermination of the partiesâ€™ agreements with respect to the commercialization of CNCT19 (the â€œArbitration Proceedingâ€).Â Inthe Asset Freezing Order, the Fourth Intermediate Peopleâ€™s Court of Beijing Municipality, granted Juventasâ€™ applicationto freeze the Companyâ€™s assets while the Arbitration Proceeding is ongoing and decided to freeze up to RMB 250 million of the Companyâ€™s assets. To enforce the Asset Freezing Order, the court has decided to freeze the transfer of certain equity interest the Company ownsin its subsidiaries in the P.R.C. No other asset has been affected. The Company does not expect that such action will have material adverseeffects on its day-to-day operations.Â The Company will continue to vigorously assertand enforce its rights against Juventas through all available legal means. The Company cannot predict right now the final outcome of theArbitration Proceeding or how the partiesâ€™ dispute would ultimately be resolved.Â Forward-Looking StatementsÂ This 6-K contains forward-looking statements.These statements are made under the â€œsafe harborâ€ provisions of the U.S. Private Securities Litigation Reform Act of 1995.These forward-looking statements can be identified by terminology such as â€œwill,â€ â€œexpects,â€ â€œanticipates,â€ â€œfuture,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œestimates,â€ â€œconfidentâ€ and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securitiesand Exchange Commission (the â€œSECâ€), in its annual report to shareholders, in press releases and other written materials andin oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, includingstatements about the Companyâ€™s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherentrisks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-lookingstatement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-lookingstatement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements containedherein.Â Â Â Â SIGNATURESÂ Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoauthorized.Â Â CASI Pharmaceuticals,Â Inc.Â Â Â By: /s/ Wei-Wu He Â Name: Wei-Wu He Â Title: ChairmanÂ & CEO Â Â Date: JanuaryÂ 21, 2025 Â Â Â Â